By partnering and collaborating with various organizations, we are able to strengthen our drug development operations. We are seeking collaborators to maximize the full potential of our lead candidate and licensing opportunities to complement our current platform. Please send business development inquiries via our Contact Us page.
Ibrexafungerp (formerly SCY-078) was initially discovered at our research facilities and developed as part of a research collaboration with Merck. Subsequently, all worldwide intellectual property, development and commercialization rights were transferred to SCYNEXIS. We are currently developing this product as a novel oral and intravenous (IV) drug for the treatment of multiple serious and often life-threatening fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.
In August 2013, we announced an agreement with R-Pharm CJSC, a leading supplier of hospital drugs in Russia, granting them exclusive rights to develop and commercialize ibrexafungerp (formerly SCY-078) in Russia, Turkey and certain Balkan, Central Asian, Middle Eastern and Northern African countries. Invasive fungal infections are a serious health concern in these countries and we are pleased to be working with R-Pharm to develop ibrexafungerp for these patients.